Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 09:31 ET | Source: Novo Nordisk A/S

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior
October 30, 2025 05:49 ET | Source: Novo Nordisk A/S

Novo Nordisk submits proposal to acquire Metsera, Inc.

Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera). The acquisition of Metsera, including its early and...
October 21, 2025 08:02 ET | Source: Novo Nordisk A/S

Notice convening an Extraordinary General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 October 2025 – Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo Nordisk A/S is called to elect new members to the Board of Directors...
October 21, 2025 07:56 ET | Source: Novo Nordisk A/S

Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors

Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of...
October 15, 2025 08:30 ET | Source: Novo Nordisk A/S

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in...
October 09, 2025 06:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbiditiesAkero Therapeutics’s FGF21...
September 18, 2025 04:45 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Ozempic® (once-weekly injectable semaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 diabetes and cardiovascular disease on Medicare versus...
September 17, 2025 17:05 ET | Source: Novo Nordisk A/S

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants losing 20% or more body weight1**Oral semaglutide 25 mg also...
September 16, 2025 06:00 ET | Source: Novo Nordisk A/S

Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme

Positive results show that the average weight loss was 12.5 kg (11.8% body weight reduction) with cagrilintide compared to 2.5 kg (2.3%) with placebo, after 68 weeks*1,2Cagrilintide was...
September 15, 2025 18:03 ET | Source: Novo Nordisk A/S

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being

Results from a real-world survey suggest that semaglutide for weight management (Wegovy®) helped suppress food noise – unwanted and intrusive thoughts about food – in addition to its established...